Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2‑negative breast cancer: A meta‑analysis of randomized controlled trials

Nahleh,Zeina; Botrus,Gehan; Dwivedi,Alok; Jennings,Michael; Nagy,Shaimaa; Tfayli,Arafat

doi:10.3892/mco.2019.1796

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2‑negative breast cancer: A meta‑analysis of randomized controlled trials

Authors:
- Zeina Nahleh
- Gehan Botrus
- Alok Dwivedi
- Michael Jennings
- Shaimaa Nagy
- Arafat Tfayli
View Affiliations

Affiliations: Department of Hematology‑Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79912, USA, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX 79912, USA, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX 79912, USA, Department of Pathology, Faculty of Medicine, Benha University, Benha 13511, Egypt, American University of Beirut Medical Center, Beirut 1107‑2020, Lebanon
Published online on: January 2, 2019 https://doi.org/10.3892/mco.2019.1796
Pages: 357-365
Copyright: © Nahleh et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several randomized clinical trials have suggested the effectiveness of bevacizumab (Bev) in early and advanced breast cancer; however, due to the increased toxicity and lack of a clear long‑term survival benefit, there is currently no defined role for Bev in breast cancer in the USA, while it has been approved in Europe. We herein sought to conduct a meta‑analysis of large randomized trials comparing the efficacy and long‑term outcome of neoadjuvant chemotherapy with Bev compared with chemotherapy without Bev in human epidermal factor receptor 2 (HER2)‑negative breast cancer. A search was conducted through PubMed and Ovid Medline databases. Among the 279 articles identified, 5 met the eligibility criteria and were included in the present analysis. A total of 2,268 patients treated with Bev and 2,278 treated without Bev were analyzed. Pathological complete response (pCR) was obtained in 35% of patients treated with Bev and in 26% of those treated without Bev. A statistically significant increase (26%) in the incidence of pCR was observed in the Bev‑treated group. However, patients treated with Bev exhibited no significant difference in the risk of disease recurrence or death. To the best of our knowledge, this is the first meta‑analysis addressing the long‑term outcomes of Bev in combination with chemotherapy in the neoadjuvant treatment of HER2‑negative breast cancer. The results confirmed the significant benefit of Bev combined with chemotherapy compared with chemotherapy alone on breast cancer response, in both triple‑negative and hormone receptor‑positive cases. However, this benefit does not translate into a long‑term disease‑free or definitive overall survival advantage. Optimizing patient selection is desirable for maximizing the long‑term benefits of Bev, while reducing cost and treatment‑related adverse effects. Future efforts directed toward the discovery of predictive markers would be crucial for identifying the subset(s) of breast cancer patients who are most likely to benefit from Bev therapy.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER Cancer Statistics Review. pp. 1975–2013. National Cancer Institute; Bethesda, MD, USA: 2016
2	DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
3	Gampenrieder SP, Rinnerthaler G and Greil R: Neoadjuvant chemotherapy and targeted therapy in breast cancer: Past, present, and future. J Oncol. 2013:7320472013. View Article : Google Scholar : PubMed/NCBI
4	Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 15:2483–2493. 1997. View Article : Google Scholar : PubMed/NCBI
5	Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, et al: ARTemis Investigators: Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial. Lancet Oncol. 16:656–666. 2015. View Article : Google Scholar : PubMed/NCBI
6	Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, et al: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat. 124:133–140. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, et al: German Breast Group Investigators: Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 24:2978–2984. 2013. View Article : Google Scholar : PubMed/NCBI
8	Levasseur N, Clemons M, Hilton J, Addison C, Robertson S, Ibrahim M and Arnaout A: Neoadjuvant endocrine therapy and window of opportunity trials: New standards in the treatment of breast cancer? Minerva Chir. 70:181–193. 2015.PubMed/NCBI
9	Dowsett M: Predictive and prognostic factors. Breast Cancer Res. 12 Suppl 4:S22010. View Article : Google Scholar : PubMed/NCBI
10	Shinkaruk S, Bayle M, Laïn G and Déléris G: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 3:95–117. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004. View Article : Google Scholar : PubMed/NCBI
12	Summers J, Cohen MH, Keegan P and Pazdur R: FDA drug approval summary: Bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 15:104–111. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gil-Gil MJ, Mesia C, Rey M and Bruna J: Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 7:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
15	Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA and Keating NL: The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: The case of bevacizumab for breast cancer. Med Care. 51:622–627. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lenzer J: FDA committee votes to withdraw bevacizumab for breast cancer. BMJ. doi.org/10.1136/bmj.d4244.
17	Cao L, Yao GY, Liu MF, Chen LJ, Hu XL and Ye CS: Neoadjuvant bevacizumab plus chemotherapy versus chemotherapy alone to treat non-metastatic breast cancer: A meta-analysis of randomised controlled trials. PLoS One. 10:e01454422015. View Article : Google Scholar : PubMed/NCBI
18	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. doi.org/10.1136/bmj.b2535.
19	Hutton B, Moher D and Cameron C: The PRISMA extension statement. Ann Intern Med. 163:566–567. 2015. View Article : Google Scholar : PubMed/NCBI
20	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
21	Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
22	Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 366:310–320. 2012. View Article : Google Scholar : PubMed/NCBI
23	von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15:747–756. 2014. View Article : Google Scholar : PubMed/NCBI
24	Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, et al: SWOG S0800 (NCI CDR0000636131): Addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 158:485–495. 2016. View Article : Google Scholar : PubMed/NCBI
25	von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, et al: German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366:299–309. 2012. View Article : Google Scholar : PubMed/NCBI
26	Berry DA and Hudis CA: Neoadjuvant therapy in breast cancer as a basis for drug approval. JAMA Oncol. 1:875–876. 2015. View Article : Google Scholar : PubMed/NCBI
27	Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 116:2610–2621. 2006. View Article : Google Scholar : PubMed/NCBI
28	Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, et al: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol. 14:933–942. 2013. View Article : Google Scholar : PubMed/NCBI
29	Miller K, O'Neill AM, Dang CT, et al: Bevacizumab in the adjuvant treatment of HER2 negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. 2014 ASCO Annual Meeting (abstract 500). J Clin Oncol. 32 Suppl 15:5002014. View Article : Google Scholar
30	Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, et al: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial. J Transl Med. 13:2582015. View Article : Google Scholar : PubMed/NCBI
31	Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, et al: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13:724–733. 2012. View Article : Google Scholar : PubMed/NCBI
32	Massuti Sureda B, Jantus-Lewintre E, Gonzalez-Larriba JL, Rodriguez Abreu D, Juan OJ, Domine M, Provencio Pulla M, de Castro J, Camps C and Rosell R: 37PDSNPS in angiogenic factors as predictive markers for outcome in patients (P) with advanced non-squamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel (CP), and bavacizumab (BEV). Final results of angiomet spanish lung cancer group trial. Ann Oncol. 26 Suppl 1:i102015. View Article : Google Scholar
33	Mattern J, Koomägi R and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 73:931–934. 1996. View Article : Google Scholar : PubMed/NCBI
34	Sikov WM, Barry WT, Hoadley KA, et al: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc). Cancer Res. 75:S4–S05. 2015. View Article : Google Scholar